Treatment News : Early Access Program for Integrase Inhibitor Dolutegravir Launched

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 5, 2012

Early Access Program for Integrase Inhibitor Dolutegravir Launched

ViiV Healthcare and Shionogi have launched an expanded access program (EAP) for its integrase inhibitor dolutegravir (S/GSK134957), according to details now available on ViiV’s website.

The new program is of potential importance for people living with HIV in need of new treatment options, including those with resistance to Merck’s Isentress (raltegravir) or Gilead Science’s experimental integrase inhibitor elvitegravir, and are unable to access the companies’ Phase III clinical trials of the drug. Activists warn, however, that enrollment in this EAP requires caution, particularly for those who have no other fully active antiretrovirals (ARVs) to combine with dolutegravir and run the risk of developing rapid resistance to the drug.

EAPs essentially allow new antiretrovirals (ARVs) to be made available before they are approved to people living with serious or life-threatening conditions who are unable to participate in clinical trials. They are permitted by regulatory agencies, such as the U.S. Food and Drug Administration (FDA), under special circumstances, where the potential benefits may outweigh the risks.

The dolutegravir EAP will be continued until the drug has been approved by the FDA and is made available through pharmacies.

The dolutegravir EAP is open to all men and women 18 years of age and older who are unable to construct a viable ARV regimen with commercially available medications. To qualify, all patients must also have a viral load of at least 400 copies within three months of enrolling and have documented HIV resistance to Isentress or elvitegravir.

Among the exclusion criteria—factors that may disqualify someone from participating in the EAP—include signs of significant liver or kidney impairment, pregnancy or breastfeeding and being eligible, and having access to, an actively enrolling dolutegravir Phase III clinical trial.

The dolutegravir EAP is now open and accepting participants in the United States and Canada. For people living with HIV in Europe and other regions, ViiV and Shionogi anticipate that its EAP will start to open by April 2012, as local regulatory and ethics approvals are obtained.

To enroll in the EAP, patients must be working with a health care provider who has been approved to participate in the program. If a health care provider is not already participating, he or she may contact PAREXEL, an operating partner that has been designated by the companies to oversee the program.

Health care providers can learn more by contacting PAREXEL at: dolutegravir-eap@parexel.com.

Search: dolutegravir, S/GSK134957, ViiV, Shionogi, expanded access program, EAP, Phase III, integrase inhibitor


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dambitious
    Gone
    New York


    romanticseattle
    Tacoma
    Washington


    latinpozdallas
    Dallas
    Texas


    clintonjrsyr
    syracuse
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.